IASO Cancer


+41 79 905 4073

DCT plus Virus therapy

Fighting cancer with a virus

Possible uses of virus therapy

In the palliative situation, i.e., when the tumour could not be removed and remains in the patient, when metastases have formed and other organs are affected, we have a response rate of 60 to 65 percent with dendritic cell therapy alone, depending on the form of cancer according to WHO criteria.

This can be increased with viral therapy.

In the laboratory, the patient’s dendritic cells are combined with the cancer antigen and a special virus that can only attack cancer cells.

This helps the immune system to better recognise the enemy, the cancer cell.


Defeat cancer through dendritic cell therapy combined with a virus

Oncolytic virus therapy is an official, innovative, and effective cancer treatment using a special virus that can find and destroy cancer cells in the human body.


Tumour cells lack an innate immune defense against viruses

More than 100 years ago, doctors observed for the first time that patients were cured of their cancer after infectious diseases. Systematic studies have shown that there are types of viruses that specifically attack cancer cells. They are called oncolytic viruses. In October 2015, an oncolytic virus was approved for the first time in the USA, and in 2016 also in Europe and Australia, for the treatment of malignant melanoma


Unmask cancer cells and fight them with the patient's own vaccine

Once a tumour has taken up residence in a person's body, it develops biological camouflage mechanisms to evade the immune system's grasp. Through repeated application of the combination of dendritic cells with the virus, the patient's immune system is enabled to recognize these camouflage mechanisms. The body can then recognize the tumour cells in the body as dangerous and fight them effectively. As with a conventional vaccination, the immune system can form an immunological memory against the tumour antigens, so that a long-term effect is given.


Tumour cells cannot defend themselves against viruses

In contrast to healthy cells, tumour cells cannot produce enough interferon to defend themselves against infection with a VIrus. Viruses can therefore multiply unhindered in the cancer cells. However, the immune system reacts to the infection with the virus and triggers a defense reaction against the virus-infected tumour cells. Healthy body cells can prevent an attack by the virus by producing interferon and thus stopping the viruses. Healthy cells are not damaged by this therapy, which means that virus treatment is almost free of side effects.


The Newcastle Disease Virus (NDV) can only replicate in cancer cells

The Newcastle Disease Virus (NDV) reproduces exclusively in human tumour cells without damaging healthy cells. It is completely harmless to humans. Through infection, the tumour cells send out danger signals that alert and activate the immune system. In this way, NDV potentiates the effect of dendritic cell therapy.


An effective therapy with almost no side effects

The oncolytic virus therapy selectively destroys cancer cells without affecting the body's healthy cells. This therapy has no side effects.

As with a conventional vaccination, the immune system can form an immunological memory against the tumour antigens, so that a long-term effect is given.
Oncolytic virus therapy can be used at different stages of cancer and during all cancer treatment processes.

The course of treatment and the costs

Before starting therapy, the medical records are reviewed by the doctors at the clinic. This can take place during an initial consultation at the clinic or via teleconference with the patient. A blood test is required to check the immune system and tumour activity. This can be done at the clinic or at the patient’s home in an appropriately trained laboratory.

This is followed by the development of the therapy strategy – until this is ready it takes about 2 weeks.

First therapy unit - first vaccination cycle

Duration: 8 days

This starts with the blood collection – see treatment procedure dendritic cells-.

Unlike dendritic cell therapy where patients go home between blood collection and injection of activated cells, patients stay at the clinic. For 8 days. During this time, the virus is administered, combined with hyperthermia applications, vitamins and trace elements.

The Second Therapy Unit- Second Vaccination Cycle

Duration 8 days

This is a second cycle with the dendritic cells, the virus administration and hyperthermia plus vitamins and trace elements.

After 3 weeks the success of the vaccination is examined

The costs

Costs can be different for each patient, as the therapy offer is tailored to each individual patient.

As a guideline:

Cost of laboratory tests:

  • these can be done locally in most countries and will probably be covered by health insurance: EUR 4’000 to EUR 7’000 
  • Costs per vaccination cycle – therapy unit: about EUR 28’000

The total cost for 2 therapy sessions is at least EUR 60’000